Companies: 10,795·Total market cap: $144.5T
Abbott Laboratories

Abbott Laboratories

ABTNYSEHealthcare● Active
$90.50
$-0.57(-0.63%)
Market Cap$157.6B
P/E Ratio—
52W High$139.06
52W Low$81.97
Cash on HandFinancialsRevenue

Abbott Laboratories (ABT) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ABT · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$8.94B▲ +12.2% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$8.52B
cashAndCashEquivalents
Short-Term Investments
$417.0M
shortTermInvestments
YoY Change vs Prior Year
+12.2%
vs prior fiscal year
Latest Quarter
$7.29B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$8.94BCash on Hand
Total Debt$15.07BTotal Debt
Net Cash / Net Debt−$6.13BNet Debt Position
Cash vs Debt Ratio
Cash 37%Debt 63%

Abbott Laboratories carries a net debt position of $6.13B. Total debt ($15.07B) exceeds cash on hand ($8.94B). Abbott Laboratories cash vs debt ratio: 37% cash / 63% debt.

Net Cash = Cash & ST Investments − Total Debt$8.94B − $15.07B = −$6.13B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
ABT annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$8.94B+12.2%
Dec 31, 2024$7.97B+9.5%
Dec 31, 2023$7.28B-28.4%
Dec 31, 2022$10.17B-0.8%
Dec 31, 2021$10.25B+43.4%
ABT cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%
#3
Abbott Laboratories
Abbott LaboratoriesYOU
ABT
$8.94B5.7%
#4
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Abbott Laboratories (ABT) cash on hand as of December 31, 2025 is $8.94B, comprising $8.52B in cash and cash equivalents (CCE) plus $417.0M in short-term investments — reported as Abbott Laboratories cash and short-term investments on the balance sheet (10-K filing). Also referred to as Abbott Laboratories cash reserves or cash position.

Abbott Laboratories annual cash on hand history shows increased +12.2% in 2025: increased +12.2% in 2025. Abbott Laboratories cash reserves in 2025 reflect the company's capital allocation strategy.

Abbott Laboratories carries total debt of $15.07B against cash of $8.94B, resulting in a net debt position of -$6.13B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

ABT cash on hand · 5 questions

As of December 31, 2025, Abbott Laboratories (ABT) has $8.94B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $8.52B in cash and cash equivalents (CCE) plus $417,000,000 in short-term investments. Latest quarter (March 31, 2026): $7.29B. Data sourced from the annual 10-K filing via FMP.

ABT cash on handABT cash reservesABT cash 2025how much cash does ABT have

▸ Source: FMP /balance-sheet-statement · US GAAP · Abbott Laboratories · Abbott Laboratories SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025